MAPRE2 and hepatocellular carcinoma: Liu et al. [32] concluded that EB1 could act as an oncogene through its involvement in the activation of the WNT signalling pathway in head and neck cancers and Orimo et al. [33] suggested that EB1 might represent a prognostic biomarker in hepatocellular carcinoma.